bluuebunny/crossref_metadata_2025 huggingface dataset:
Mechanisms of lung endothelial cell injury and survival in pulmonary arterial hypertension
Authors: Marinho Ygor , Villarreal Elizabeth S. , Loya Omar , Oliveira Suellen D.
Published: October 2024

Pulmonary arterial hypertension (PAH) is a progressive, chronic, and incurable inflammatory pulmonary vascular disease characterized by significant sex bias and largely unexplored microbial-associated molecular mechanisms that may influence its development and sex prevalence across various subgroups. PAH can be subclassified as idiopathic, heritable, or associated with conditions such as connective tissue diseases, congenital heart defects, liver disease, infections, and chronic exposure to drugs or toxins. During PAH progression, lung vascular endothelial cells (ECs) undergo dramatic morphofunctional transformations in response to acute and chronic inflammation. These transformations include the appearance and expansion of abnormal vascular cell phenotypes such as those derived from apoptosis-resistant cell growth and endothelial-to-mesenchymal transition (EndoMT). Compelling evidence indicates that these endothelial phenotypes seem to be triggered by chronic lung vascular injury and dysfunction, often characterized by reduced secretion of vasoactive molecules like nitric oxide (NO) and exacerbated response to vasoconstrictors such as Endothelin-1 (ET-1), both long-term known contributors of PAH pathogenesis. This review sheds light on the mechanisms of EC dysfunction, apoptosis, and EndoMT in PAH, aiming to unravel the intricate interactions between ECs, pathogens, and other cell types that drive the onset and progression of this devastating disease. Ultimately, we hope to provide an overview of the complex functions of lung vascular ECs in PAH, inspiring novel therapeutic strategies that target these dysfunctional cells to improve the treatment landscape for PAH, particularly in the face of current and emerging global pathogenic threats.
Digital Life Balance and Need for Online Social Feedback: Cross–Cultural Psychometric Analysis in Brazil
Authors: Lima-Costa Ariela Raissa , Tosti Anna Enrica , Bonfá-Araujo Bruno , Duradoni Mirko
Published: October 2024

In the contemporary digital era, the extensive integration of information and communication technologies (ICT) has significantly changed offline activities, including communication, shopping, and media consumption. This integration has been accelerated by the COVID‐19 pandemic, leading to increased reliance on ICT for work, education, socializing, and accessing essential services. Consequently, there is growing concern about the impact of ICT on well‐being, particularly regarding psychological and financial health, as well as the association with psychiatric disorders. This study is aimed at exploring the psychometric properties of two scales adapted for the Brazilian context: the Digital Life Balance (DLB) scale and the Need for Online Social Feedback (NfOSF) scale. These scales measure individuals’ perceived balance between online and offline activities and their need for social validation online, respectively. Using a sample of 220 Brazilian individuals (50.9% female, 43.6% male, mean age = 34.96 years, SD = 11.32), we conducted confirmatory factor analysis (CFA) to assess the scales’ factor structures and test the reliability and validity of the two measures. The results demonstrated good fit indices and reliable internal consistency for both scales. Additionally, metric invariance between Brazilian and Italian samples was established, supporting cross‐cultural applicability. External validity was examined through correlations with time spent on social media and the perceived importance of followers. Findings indicate that higher DLB is associated with less time spent online, while greater NfOSF correlates with higher importance placed on social media followers. These insights highlight the importance of understanding digital balance and the role of social feedback in ICT use, contributing to the effective screening of potential dysfunctional ICT use in Brazil. As a result of this study, validated Brazilian versions of the NfOSF and DLB scales were successfully obtained, offering valuable tools for assessing DLB and the NfOSF in the Brazilian context.
Titanium‐Coated Extremely Sensitive SPR Biosensor for Cancer Cell Detection
Authors: Hoque Abdullah Mohammad Tanvirul , Altabatabaie Kusay Faisal , Habib Md. Ahasan , Ahsan Mominul , Haider Julfikar
Published: October 2024

In this study, a D‐shaped, extremely sensitive surface plasmon resonance (SPR) sensor with a blue shift characteristic is proposed that can be used to identify various malignant cancer cells. A sensing layer made of titanium is inserted to produce intense sensitivity. For the simulation and numerical evaluation of the proposed biosensor, we used the finite element method (FEM) and the COMSOL Multiphysics 5.6 software. To regulate how much light passes through the sensor, which incites the released electrons at the surface of the plasmonic material, air holes in different radii are used. The characteristics that make our proposed sensor superior to other D‐shaped SPR sensors are—it gives an excellent amplitude sensitivity (AS) of 200 RIU−1 also ensures extremely high wavelength sensitivity (WS) spanning from 34,350 to 42,145 nm/RIU with an outstanding spectral resolution of 2.37 × 10−6 RIU. Furthermore, the R2 (0.9966) value is also extremely close to 1 which ensures the quality of our sensor regarding its performance. The given sensor is tailored for four vital human cancers, which are blood cancer, skin cancer, cervical cancer, and adrenal gland cancer. Here, optimization of the structural geometric parameters, plasmonic materials, and material thickness are also conducted in search of the best functionality of the sensor. The offered structure, nonetheless, can be an obvious prologue in the case of the crucial human cancer detection platform due to its mild sensing performances.
Numerical Simulation Study on In‐Depth Profile Control of Core–Shell Coagulation System Considering the Time‐Variation of Permeability
Authors: Sun Zhaobo , Cao Shuchun , Wang Gongchang , Jia Xiaofei , Ning Guoqing
Published: October 2024

The coring data in high water‐cut oilfields indicates that the reservoir permeability will change continuously with water flooding, while the existing reservoir numerical simulation software cannot consider the time‐varying phenomenon of permeability. With the enhancement of reservoir heterogeneity, the near‐wellbore profile control fails to stabilize the oil production and control the water cut. The in‐depth profile control has been widely used in oilfields as a new technology, and the types of profile control agents are diverse, with a complex mechanism that cannot be effectively described by the existing conventional numerical simulation software. Considering these two phenomena comprehensively, a new three‐dimensional, three‐phase, six‐component mathematical model that can take into account the time‐varying phenomenon of reservoir permeability is proposed for a new kind of in‐depth profile control system, namely, the core–shell coagulation system, and an integrated numerical simulation software is developed. The mechanism of the in‐depth profile control system can be perfectly demonstrated in the simulator with time‐variation of permeability. The results of sensitivity analysis show that the effect is influenced by three factors: the mix slug injecting concentration, the coagulant aid slug volume, and the concentration of the suspension dispersing agent.
Two‐Phase Relative Permeability Curves of Bingham Heavy Oil Under Different Types of Wettability: A Theoretical Model
Authors: Wang Qing , Li Yu , Peng Chao , Peng Jiao , Fu Jingyu , Liu Renjie , Liu Huiqing , Li Jiaxin , Peng Hao
Published: October 2024

As an important and universal petrophysics of heavy oil reservoirs, the two‐phase flow ability inside porous medium is vital for heavy oil development. Utilizing the laminar flow theory and an ideal pore structure, especially cylinder model, the function of the relative permeability of heavy oil–water with water saturation is derived by incorporating the principles of momentum conservation and the characteristics of Bingham fluids, which was modified by validated experiment. Two‐phase relative permeability, considering heavy oil as non‐Newtonian fluid, is the function of water saturation, pore size, oil–water viscosity ratio, and yield stress. The results of the validated experiment show that the theoretical values calculated employing the modified equation exhibit better agreement with the experimental values, particularly when the viscosities of two‐phase fluid are great. The results of the modified two‐phase relative permeability show a decrease in water saturation interval corresponding to the two‐phase flow area and a smaller value of permeability at equal two‐phase relative permeability. The oil–water viscosity ratio in the hydrophobic pores affects the water‐phase relative permeability, although the magnitude of its influence diminishes as the viscosity ratio increases. The behavior of relative permeability in hydrophilic pores is the opposite of that in hydrophobic pores. This work can afford good application prospects for mobility control in multilayered reservoirs through the heterogeneous‐phase‐composite fluid. The saturations of the remaining oil and irreducible water also play a vital role in the prediction of permeability. The work can afford good application prospects for the flow behavior of Bingham heavy oil in pores with different types of wettability.
Clinical Outcomes of a Trifocal Versus an Extended Depth of Field Intraocular Lens in Chinese Patients With Cataract: A Prospective Cohort Study
Authors: Chen Qingzhong , Zhang Guangbin
Published: October 2024

Purpose: To compare the standard outcomes between the PanOptix and Symfony multifocal intraocular lenses (MIOLs) in Chinese patients.

Methods: This prospective observational cohort study enrolled patients with cataracts between April 2021 and December 2021 at Xiamen Eye Center Affiliated to Xiamen University. The patients were grouped in the PanOptix (TIOL group) and Symfony (EDF group) according to the IOLs implanted. Uncorrected distant, corrected distance, binocular uncorrected intermediate, and near visual acuity (UNVA), distance‐corrected intermediate and near VA (DCNVA) , defocus curve, spectacle independence, contrast sensitivity (CS), and visual disturbances were evaluated after 3 months.

Results: Forty patients (80 eyes) were enrolled in the study (20/group). Three months after the operation, UNVA (0.13 ± 0.16) and DCNVA (0.08 ± 0.08) were better in the TIOL group than in the EDF group (0.22 ± 0.08 and 0.22 ± 0.08, respectively, p = 0.003 and p < 0.001, respectively). The TIOL group achieved a better‐than‐0.15‐logMAR VA from +0.5 D to −2.5 D (40 cm). VAs of the TIOL group from −1 D (100 cm) to −4 D (25 cm) were better than in the EDF group (p < 0.05). There were no significant differences in the intermediate and far vision outcomes (p > 0.05). Total near‐vision spectacle independence was higher in the TIOL group (80%) than in the EDF group (50%) (p = 0.039).

Conclusion: Compared with EDF, TIOL leads to better near‐vision outcomes without significant differences for intermediate and distant vision outcomes.

Trial Registration: ClinicalTrials.gov identifier: ChiCTR2100044558.
Some Algebraic Classification of Semiregular Hypermodules in Connection to the Radical
Authors: Aydın Yıldız , Türkmen Burcu Nişancı
Published: October 2024

We call a Krasner right S‐hypermodule A regular if each cyclic subhypermodule of A is a direct summand of A, and we also call A semiregular if every finitely generated subhypermodule of A lies above a direct summand of A. In this study, some properties of such hypermodules are achieved. This paper consists of concentrating over the radical, as well as their connections with (semi)regularity of hypermodules. Finally, the relationship between f‐supplement submodule and semiregularity is given.
Reliable Model Predictive Vibration Control for Structures with Nonprobabilistic Uncertainties
Authors: Gong Jinglei , Wang Xiaojun
Published: October 2024

This paper proposes a novel reliable model predictive control (MPC) method for active vibration control of structure with nonprobabilistic uncertainties. First, the framework of reliable MPC is established by integrating nonprobabilistic reliability constraints into nominal MPC. Based on the first‐order Taylor expansion and first‐passage theory, an efficient nonprobabilistic reliability analysis method that is suitable for online computation is proposed. A nonprobabilistic Kalman filter is further proposed for determine system states and their uncertain region. Unlike most robust MPC approaches, the proposed reliable MPC focuses on the satisfaction of state constraints in terms of structural reliability and is more suitable for structures with stringent safety requirements. Compared to existing reliability‐based vibration control methods, reliable MPC requires no knowledge of disturbance and exhibits greater adaptability to load environments. The effectiveness and superiority of the proposed reliable MPC are validated through a numerical example and an engineering case study.
The Role of Gut Microbiota in Modulating Cancer Therapy Efficacy
Authors: Madkour Mostafa A. , Altaf Rawan A. , Sayed Zeinab S. , Yasen Noha S. , Elbary Hanan A. , Elsayed Reem A. , Mohamed Esraa N. , Toema Mohamed , Wadan Al-Hassan Soliman , Nafady Mohamed H. , El-Benhawy Sanaa A.
Published: October 2024

Gut microbiota substantially impacts pathogenic and normal immune responses and is associated with common chronic diseases. Moreover, it has a considerable effect on the efficacy of cancer therapy. Variant gut microbiota is linked with immune checkpoint inhibitors, chemo drugs, and radiotherapy resistance. Therefore, a comprehensive interpretation of the interactions between microbiota and cancer therapies is required to encourage researchers to develop new cancer prevention strategies and weaken the consequences of the different cancer therapies. This review discusses the modulating role of gut microbiota that impacts the efficacy of cancer therapies and focuses on its influence on each treatment method, in addition to delivering an overview of the gut microbiota’s role and forming relationships between bacteria, inflammation, and cancer therapies. Highlighting the mechanism of action of probiotics, antibiotics, fecal microbiota transplantation, and prebiotics promotes cancer therapies’ efficacy. Consequently, this makes the gut microbiota essential as a new adjunct augmenting the cancer therapeutic response.
Understanding the Spatial Heterogeneity Impact of Determinants on Ridership of Urban Rail Transit Across Different Passenger Groups
Authors: Qian Qian , Liu Yang , He Min , He Mingwei , Qian Huimin , Shi Zhuangbin
Published: October 2024

Accurately understanding the travel demand of urban rail transit (URT) systems is crucial for effective operational management. Despite the recognition that the diversity in human activity patterns results in different travel demands, few studies have thoroughly investigated the heterogeneity among passengers and its impact on URT ridership. This study utilizes smart card data collected from the Beijing Subway to categorize passengers into four groups: tourist passengers, flexible commuters, regular commuters, and life‐oriented passengers, based on their spatiotemporal travel patterns. Furthermore, a Multiscale Geographically Weighted Regression (MGWR) model is employed to examine the relationship between station‐level ridership of URT and its determinants, including the built environment and station properties, for each passenger group. The results indicate that the influence of these determinants on station‐level ridership varies across passenger groups and spatial scales. For instance, regular commuters exhibit lower sensitivity to accessibility on workdays, whereas those unfamiliar with the URT network are more concerned about the bus accessibility in pedestrian‐ or bicycle‐unfriendly areas. Notably, for tourist and life‐oriented passengers, the stations significantly affected by population density are concentrated in areas with a higher proportion of elderly individuals. Conversely, for flexible and regular commuters, these stations are predominantly situated in areas associated with internet technology and scientific research. These findings are valuable for policymakers in designing strategies tailored to different passenger groups to balance trip demand and capacity, thereby improving URT services and promoting a sustainable urban environment.
Supplementary Table S4 from Targeting the Sodium–Potassium Pump as a Therapeutic Strategy in Acute Myeloid Leukemia
Authors: Schneider Constanze , Spaink Hermes , Alexe Gabriela , Dharia Neekesh V. , Meyer Ashleigh , Merickel Lucy A. , Khalid Delan , Scheich Sebastian , Häupl Björn , Staudt Louis M. , Oellerich Thomas , Stegmaier Kimberly
Published: October 2024

ATP1B1 gene expression across the BloodSpot.eu normal human hematopoiesis samples
Supplementary Table S1 from Targeting the Sodium–Potassium Pump as a Therapeutic Strategy in Acute Myeloid Leukemia
Authors: Schneider Constanze , Spaink Hermes , Alexe Gabriela , Dharia Neekesh V. , Meyer Ashleigh , Merickel Lucy A. , Khalid Delan , Scheich Sebastian , Häupl Björn , Staudt Louis M. , Oellerich Thomas , Stegmaier Kimberly
Published: October 2024

Candidate gene list of selective dependencies identified analyzing DepMap dependency screen data
Supplementary Figure S8 from Targeting the Sodium–Potassium Pump as a Therapeutic Strategy in Acute Myeloid Leukemia
Authors: Schneider Constanze , Spaink Hermes , Alexe Gabriela , Dharia Neekesh V. , Meyer Ashleigh , Merickel Lucy A. , Khalid Delan , Scheich Sebastian , Häupl Björn , Staudt Louis M. , Oellerich Thomas , Stegmaier Kimberly
Published: October 2024

ATP1B1 expression across hematopoietic lineages
Supplementary Figure S7 from Targeting the Sodium–Potassium Pump as a Therapeutic Strategy in Acute Myeloid Leukemia
Authors: Schneider Constanze , Spaink Hermes , Alexe Gabriela , Dharia Neekesh V. , Meyer Ashleigh , Merickel Lucy A. , Khalid Delan , Scheich Sebastian , Häupl Björn , Staudt Louis M. , Oellerich Thomas , Stegmaier Kimberly
Published: October 2024

Isoform expression of ATP1B1
Supplementary Table S1 from Single-Stranded DNA Gap Accumulation Is a Functional Biomarker for USP1 Inhibitor Sensitivity
Authors: da Costa Alexandre A. , Somuncu Ozge , Ravindranathan Ramya , Mukkavalli Sirisha , Martignetti David B. , Nguyen Huy , Jiao Yuqing , Lamarre Benjamin P. , Sadatrezaei Golbahar , Moreau Lisa , Liu Joyce , Iyer Divya R. , Lazaro Jean-Bernard , Shapiro Geoffrey I. , Parmar Kalindi , D’Andrea Alan D.
Published: October 2024

CRISPR screen results in UWB1.289 cells treated with USP1 inhibitor versus DMSO
Supplementary Materials and Methods from Single-Stranded DNA Gap Accumulation Is a Functional Biomarker for USP1 Inhibitor Sensitivity
Authors: da Costa Alexandre A. , Somuncu Ozge , Ravindranathan Ramya , Mukkavalli Sirisha , Martignetti David B. , Nguyen Huy , Jiao Yuqing , Lamarre Benjamin P. , Sadatrezaei Golbahar , Moreau Lisa , Liu Joyce , Iyer Divya R. , Lazaro Jean-Bernard , Shapiro Geoffrey I. , Parmar Kalindi , D’Andrea Alan D.
Published: October 2024

Supplementary Materials and Methods
Supplementary Figure S2 from Targeting the Sodium–Potassium Pump as a Therapeutic Strategy in Acute Myeloid Leukemia
Authors: Schneider Constanze , Spaink Hermes , Alexe Gabriela , Dharia Neekesh V. , Meyer Ashleigh , Merickel Lucy A. , Khalid Delan , Scheich Sebastian , Häupl Björn , Staudt Louis M. , Oellerich Thomas , Stegmaier Kimberly
Published: October 2024

KO validation using TIDE PCR and cell cycle analysis
Supplementary Figure S5 from Single-Stranded DNA Gap Accumulation Is a Functional Biomarker for USP1 Inhibitor Sensitivity
Authors: da Costa Alexandre A. , Somuncu Ozge , Ravindranathan Ramya , Mukkavalli Sirisha , Martignetti David B. , Nguyen Huy , Jiao Yuqing , Lamarre Benjamin P. , Sadatrezaei Golbahar , Moreau Lisa , Liu Joyce , Iyer Divya R. , Lazaro Jean-Bernard , Shapiro Geoffrey I. , Parmar Kalindi , D’Andrea Alan D.
Published: October 2024

Supplementary Figure S5. Chemical structures of USP1 inhibitors.
Supplementary Figure S1 from Targeting the Sodium–Potassium Pump as a Therapeutic Strategy in Acute Myeloid Leukemia
Authors: Schneider Constanze , Spaink Hermes , Alexe Gabriela , Dharia Neekesh V. , Meyer Ashleigh , Merickel Lucy A. , Khalid Delan , Scheich Sebastian , Häupl Björn , Staudt Louis M. , Oellerich Thomas , Stegmaier Kimberly
Published: October 2024

Candidate gene selection based on the introduced features
Figure S7 from FANCI Inhibition Induces PARP1 Redistribution to Enhance the Efficacy of PARP Inhibitors in Breast Cancer
Authors: Huang Yu-Zhou , Sang Ming-Yi , Xi Pei-Wen , Xu Ruo-Xi , Cai Meng-Yuan , Wang Zi-Wen , Zhao Jian-Yi , Li Yi-Han , Wei Ji-Fu , Ding Qiang
Published: October 2024

Figure S7 illustrates the enhanced sensitivity of breast cancer cells to talazoparib by FANCI knockdown.
Figure S5 from FANCI Inhibition Induces PARP1 Redistribution to Enhance the Efficacy of PARP Inhibitors in Breast Cancer
Authors: Huang Yu-Zhou , Sang Ming-Yi , Xi Pei-Wen , Xu Ruo-Xi , Cai Meng-Yuan , Wang Zi-Wen , Zhao Jian-Yi , Li Yi-Han , Wei Ji-Fu , Ding Qiang
Published: October 2024

Figure S5 presents a comprehensive analysis of the interaction between FANCI and PARP1.
Figure S3 from FANCI Inhibition Induces PARP1 Redistribution to Enhance the Efficacy of PARP Inhibitors in Breast Cancer
Authors: Huang Yu-Zhou , Sang Ming-Yi , Xi Pei-Wen , Xu Ruo-Xi , Cai Meng-Yuan , Wang Zi-Wen , Zhao Jian-Yi , Li Yi-Han , Wei Ji-Fu , Ding Qiang
Published: October 2024

Figure S3 shows FANCI overexpression facilitates the proliferation of breast cancer cells.
Supplementary Data from Natural Killer Cell Regulation of Breast Cancer Stem Cells Mediates Metastatic Dormancy
Authors: Bushnell Grace G. , Sharma Deeksha , Wilmot Henry C. , Zheng Michelle , Fashina Toluwaleke D. , Hutchens Chloe M. , Osipov Samuel , Burness Monika , Wicha Max S.
Published: October 2024

Supplemental figures and captions
Supplementary Data from Cancer-Associated Fibroblasts Expressing Sulfatase 1 Facilitate VEGFA-Dependent Microenvironmental Remodeling to Support Colorectal Cancer
Authors: Wang Huijuan , Chen Jiaxin , Chen Xiaoyu , Liu Yingqiang , Wang Jiawei , Meng Qing , Wang Huogang , He Ying , Song Yujia , Li Jingyun , Ju Zhenyu , Xiao Peng , Qian Junbin , Song Zhangfa
Published: October 2024

supplementary materials 1.
Supplementary Data from Cancer-Associated Fibroblasts Expressing Sulfatase 1 Facilitate VEGFA-Dependent Microenvironmental Remodeling to Support Colorectal Cancer
Authors: Wang Huijuan , Chen Jiaxin , Chen Xiaoyu , Liu Yingqiang , Wang Jiawei , Meng Qing , Wang Huogang , He Ying , Song Yujia , Li Jingyun , Ju Zhenyu , Xiao Peng , Qian Junbin , Song Zhangfa
Published: October 2024

supplementary materials 2.
Figure S6 from Cancer-Associated Fibroblasts Expressing Sulfatase 1 Facilitate VEGFA-Dependent Microenvironmental Remodeling to Support Colorectal Cancer
Authors: Wang Huijuan , Chen Jiaxin , Chen Xiaoyu , Liu Yingqiang , Wang Jiawei , Meng Qing , Wang Huogang , He Ying , Song Yujia , Li Jingyun , Ju Zhenyu , Xiao Peng , Qian Junbin , Song Zhangfa
Published: October 2024

Figure S6.
Figure S4 from Cancer-Associated Fibroblasts Expressing Sulfatase 1 Facilitate VEGFA-Dependent Microenvironmental Remodeling to Support Colorectal Cancer
Authors: Wang Huijuan , Chen Jiaxin , Chen Xiaoyu , Liu Yingqiang , Wang Jiawei , Meng Qing , Wang Huogang , He Ying , Song Yujia , Li Jingyun , Ju Zhenyu , Xiao Peng , Qian Junbin , Song Zhangfa
Published: October 2024

Figure S4.
Figure S3 from Cancer-Associated Fibroblasts Expressing Sulfatase 1 Facilitate VEGFA-Dependent Microenvironmental Remodeling to Support Colorectal Cancer
Authors: Wang Huijuan , Chen Jiaxin , Chen Xiaoyu , Liu Yingqiang , Wang Jiawei , Meng Qing , Wang Huogang , He Ying , Song Yujia , Li Jingyun , Ju Zhenyu , Xiao Peng , Qian Junbin , Song Zhangfa
Published: October 2024

Figure S3.
Supplementary Table 2 from The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Tumors
Authors: Cadzow Louise , Brenneman Jehrod , Tobin Erica , Sullivan Pamela , Nayak Sumeet , Ali Janid A. , Shenker Sol , Griffith Jim , McGuire Michael , Grasberger Paula , Mishina Yuji , Murray Morgan , Dodson Anne E. , Gannon Hugh , Krall Elsa , Hixon Jeff , Chipumuro Edmond , Sinkevicius Kerstin , Gokhale Prafulla C. , Ganapathy Suthakar , Matulonis Ursula A. , Liu Joyce F. , Olaharski Andrew , Sangurdekar Dipen , Liu Hanlan , Wilt Jeremy , Schlabach Michael , Stegmeier Frank , Wylie Andrew A.
Published: October 2024

List of antibodies used for immunoblotting
Supplementary Table 1 from The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Tumors
Authors: Cadzow Louise , Brenneman Jehrod , Tobin Erica , Sullivan Pamela , Nayak Sumeet , Ali Janid A. , Shenker Sol , Griffith Jim , McGuire Michael , Grasberger Paula , Mishina Yuji , Murray Morgan , Dodson Anne E. , Gannon Hugh , Krall Elsa , Hixon Jeff , Chipumuro Edmond , Sinkevicius Kerstin , Gokhale Prafulla C. , Ganapathy Suthakar , Matulonis Ursula A. , Liu Joyce F. , Olaharski Andrew , Sangurdekar Dipen , Liu Hanlan , Wilt Jeremy , Schlabach Michael , Stegmeier Frank , Wylie Andrew A.
Published: October 2024

Cell line vendor and growth media
Data from A Genomics-Driven Artificial Intelligence–Based Model Classifies Breast Invasive Lobular Carcinoma and Discovers CDH1 Inactivating Mechanisms
Authors: Pareja Fresia , Dopeso Higinio , Wang Yi Kan , Gazzo Andrea M. , Brown David N. , Banerjee Monami , Selenica Pier , Bernhard Jan H. , Derakhshan Fatemeh , da Silva Edaise M. , Colon-Cartagena Lorraine , Basili Thais , Marra Antonio , Sue Jillian , Ye Qiqi , Da Cruz Paula Arnaud , Yeni Yildirim Selma , Pei Xin , Safonov Anton , Green Hunter , Gill Kaitlyn Y. , Zhu Yingjie , Lee Matthew C.H. , Godrich Ran A. , Casson Adam , Weigelt Britta , Riaz Nadeem , Wen Hannah Y. , Brogi Edi , Mandelker Diana L. , Hanna Matthew G. , Kunz Jeremy D. , Rothrock Brandon , Chandarlapaty Sarat , Kanan Christopher , Oakley Joe , Klimstra David S. , Fuchs Thomas J. , Reis-Filho Jorge S.
Published: October 2024

Abstract
Artificial intelligence (AI) systems can improve cancer diagnosis, yet their development often relies on subjective histologic features as ground truth for training. Herein, we developed an AI model applied to histologic whole-slide images using CDH1 biallelic mutations, pathognomonic for invasive lobular carcinoma (ILC) in breast neoplasms, as ground truth. The model accurately predicted CDH1 biallelic mutations (accuracy = 0.95) and diagnosed ILC (accuracy = 0.96). A total of 74% of samples classified by the AI model as having CDH1 biallelic mutations but lacking these alterations displayed alternative CDH1 inactivating mechanisms, including a deleterious CDH1 fusion gene and noncoding CDH1 genetic alterations. Analysis of internal and external validation cohorts demonstrated 0.95 and 0.89 accuracy for ILC diagnosis, respectively. The latent features of the AI model correlated with human-explainable histopathologic features. Taken together, this study reports the construction of an AI algorithm trained using a genetic rather than histologic ground truth that can robustly classify ILCs and uncover CDH1 inactivating mechanisms, providing the basis for orthogonal ground truth utilization for development of diagnostic AI models applied to whole-slide image.

Significance: Genetic alterations linked to strong genotypic–phenotypic correlations can be utilized to develop AI systems applied to pathology that facilitate cancer diagnosis and biologic discoveries.
Data from The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Tumors
Authors: Cadzow Louise , Brenneman Jehrod , Tobin Erica , Sullivan Pamela , Nayak Sumeet , Ali Janid A. , Shenker Sol , Griffith Jim , McGuire Michael , Grasberger Paula , Mishina Yuji , Murray Morgan , Dodson Anne E. , Gannon Hugh , Krall Elsa , Hixon Jeff , Chipumuro Edmond , Sinkevicius Kerstin , Gokhale Prafulla C. , Ganapathy Suthakar , Matulonis Ursula A. , Liu Joyce F. , Olaharski Andrew , Sangurdekar Dipen , Liu Hanlan , Wilt Jeremy , Schlabach Michael , Stegmeier Frank , Wylie Andrew A.
Published: October 2024

Abstract
Defects in DNA repair pathways play a pivotal role in tumor evolution and resistance to therapy. At the same time, they create vulnerabilities that render tumors dependent on the remaining DNA repair processes. This phenomenon is exemplified by the clinical activity of PARP inhibitors in tumors with homologous recombination (HR) repair defects, such as tumors with inactivating mutations in BRCA1 or BRCA2. However, the development of resistance to PARP inhibitors in BRCA-mutant tumors represents a high unmet clinical need. In this study, we identified deubiquitinase ubiquitin-specific peptidase-1 (USP1) as a critical dependency in tumors with BRCA mutations or other forms of HR deficiency and developed KSQ-4279, the first potent and selective USP1 inhibitor to enter clinical testing. The combination of KSQ-4279 with a PARP inhibitor was well tolerated and induced durable tumor regression across several patient-derived PARP-resistant models. These findings indicate that USP1 inhibitors represent a promising therapeutic strategy for overcoming PARP inhibitor resistance in patients with BRCA-mutant/HR-deficient tumors and support continued testing in clinical trials.

Significance: KSQ-4279 is a potent and selective inhibitor of USP1 that induces regression of PARP inhibitor–resistant tumors when dosed in combination with PARP inhibitors, addressing an unmet clinical need for BRCA-mutant tumors.
The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Tumors
Authors: Cadzow Louise , Brenneman Jehrod , Tobin Erica , Sullivan Pamela , Nayak Sumeet , Ali Janid A. , Shenker Sol , Griffith Jim , McGuire Michael , Grasberger Paula , Mishina Yuji , Murray Morgan , Dodson Anne E. , Gannon Hugh , Krall Elsa , Hixon Jeff , Chipumuro Edmond , Sinkevicius Kerstin , Gokhale Prafulla C. , Ganapathy Suthakar , Matulonis Ursula A. , Liu Joyce F. , Olaharski Andrew , Sangurdekar Dipen , Liu Hanlan , Wilt Jeremy , Schlabach Michael , Stegmeier Frank , Wylie Andrew A.
Published: October 2024

Defects in DNA repair pathways play a pivotal role in tumor evolution and resistance to therapy. At the same time, they create vulnerabilities that render tumors dependent on the remaining DNA repair processes. This phenomenon is exemplified by the clinical activity of PARP inhibitors in tumors with homologous recombination (HR) repair defects, such as tumors with inactivating mutations in BRCA1 or BRCA2. However, the development of resistance to PARP inhibitors in BRCA-mutant tumors represents a high unmet clinical need. In this study, we identified deubiquitinase ubiquitin-specific peptidase-1 (USP1) as a critical dependency in tumors with BRCA mutations or other forms of HR deficiency and developed KSQ-4279, the first potent and selective USP1 inhibitor to enter clinical testing. The combination of KSQ-4279 with a PARP inhibitor was well tolerated and induced durable tumor regression across several patient-derived PARP-resistant models. These findings indicate that USP1 inhibitors represent a promising therapeutic strategy for overcoming PARP inhibitor resistance in patients with BRCA-mutant/HR-deficient tumors and support continued testing in clinical trials.

Significance: KSQ-4279 is a potent and selective inhibitor of USP1 that induces regression of PARP inhibitor–resistant tumors when dosed in combination with PARP inhibitors, addressing an unmet clinical need for BRCA-mutant tumors.
Supplementary Figure S9 from KIR2DL2/DL3+NKs and Helios+Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer
Authors: Santagata Sara , Trotta Anna Maria , D’Alterio Crescenzo , Napolitano Maria , Rea Giuseppina , Di Napoli Marilena , Portella Luigi , Ieranò Caterina , Guardascione Giuseppe , Coppola Elisabetta , Caux Christophe , Dubois Bertrand , Boyle Helen J. , Carles Joan , Rossetti Sabrina , Azzaro Rosa , Feroce Florinda , Perdonà Sisto , Fordellone Mario , Bello Anna Maria , Califano Daniela , Chiodini Paolo , Pignata Sandro , Scala Stefania
Published: October 2024

Supplementary Figure S9. Association between the KIR2DL2/DL3+NKs/Helios+Tregs values and response to nivolumab treatment.
Supplementary Table S2 from Pembrolizumab and Cabozantinib in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Long-term Survival Update with a Biomarker Analysis
Authors: Saba Nabil F. , Chaudhary Ritu , Kirtane Kedar , Marra Angelo , Ekpenyong Asari , McCook-Veal Ashley , Schmitt Nicole C. , Gross Jennifer H. , Patel Mihir R. , Remick Jill , Bates James E. , McDonald Mark W. , Rudra Soumon F. , Stokes William A. , Biernacki Maria , Song Xiaofei , Slebos Robbert J.C. , Liu Yuan , Steuer Conor E. , Shin Dong M. , Teng Yong , Chung Christine H.
Published: October 2024

Supplementary Table S2. OS versus lymphoid markers.
Supplementary Figure S1 from YAP1 Status Defines Two Intrinsic Subtypes of LCNEC with Distinct Molecular Features and Therapeutic Vulnerabilities
Authors: Stewart C. Allison , Diao Lixia , Xi Yuanxin , Wang Runsheng , Ramkumar Kavya , Serrano Alejandra G. , Tanimoto Azusa , Rodriguez B. Leticia , Morris Benjamin B. , Shen Li , Zhang Bingnan , Yang Yan , Hamad Samera H. , Cardnell Robert J. , Duarte Alberto , Sahu Moushumi , Novegil Veronica Y. , Weissman Bernard E. , Frumovitz Michael , Kalhor Neda , Solis Soto Luisa , da Rocha Pedro , Vokes Natalie , Gibbons Don L. , Wang Jing , Heymach John V. , Glisson Bonnie , Byers Lauren Averett , Gay Carl M.
Published: October 2024

Supplementary Figure S1. YAP1 is bimodal in LCNEC.
Table 1 from A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Authors: Coveler Andrew L. , Reilley Matthew J. , Zalupski Mark , Macarulla Teresa , Fountzilas Christos , Ponz-Sarvisé Mariano , Nagrial Adnan , Uboha Nataliya V. , Frentzas Sophia , Overman Michael , Noonan Anne , Messersmith Wells A. , Pavlakis Nick , Mettu Niharika B. , Bisha Ina , Wang Ying , Smith Paul , Murtomaki Elina , Bielska Agata A. , Bragulat Veronique , Cooper Zachary A. , Kumar Rakesh , Spigel David R.
Published: October 2024

Patient demographics and disease characteristics in the dose-expansion phase (intent-to-treat population; N = 170).
Supplementary Table S2 from Integrative Multiomic Profiling of Triple-Negative Breast Cancer for Identifying Suitable Therapies
Authors: Jovanović Bojana , Church Sarah E. , Gorman Kara M. , North Khrystyna , Richardson Edward T. , DiLullo Molly , Attaya Victoria , Kasparian Julie , Mohammed-Abreu Ayesha , Kirkner Gregory , Hughes Melissa E. , Lin Nancy U. , Mittendorf Elizabeth A. , Schnitt Stuart J. , Tolaney Sara M. , Goel Shom
Published: October 2024

Supplementary Table S2. Clinical data with matched immunohistochemistry, mutation status and gene expression.
Supplementary Figure S5 from A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Authors: Coveler Andrew L. , Reilley Matthew J. , Zalupski Mark , Macarulla Teresa , Fountzilas Christos , Ponz-Sarvisé Mariano , Nagrial Adnan , Uboha Nataliya V. , Frentzas Sophia , Overman Michael , Noonan Anne , Messersmith Wells A. , Pavlakis Nick , Mettu Niharika B. , Bisha Ina , Wang Ying , Smith Paul , Murtomaki Elina , Bielska Agata A. , Bragulat Veronique , Cooper Zachary A. , Kumar Rakesh , Spigel David R.
Published: October 2024

Baseline median variant allelic frequency (VAF) by KRAS status (A), exploratory OS and PFS stratified by baseline median VAF (B) and distribution of KRAS mutation status (C), VAF (D) and blood TMB (E) by arm
Supplementary Figure S2 from A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Authors: Coveler Andrew L. , Reilley Matthew J. , Zalupski Mark , Macarulla Teresa , Fountzilas Christos , Ponz-Sarvisé Mariano , Nagrial Adnan , Uboha Nataliya V. , Frentzas Sophia , Overman Michael , Noonan Anne , Messersmith Wells A. , Pavlakis Nick , Mettu Niharika B. , Bisha Ina , Wang Ying , Smith Paul , Murtomaki Elina , Bielska Agata A. , Bragulat Veronique , Cooper Zachary A. , Kumar Rakesh , Spigel David R.
Published: October 2024

Exploratory overall survival analysis of oleclumab + durvalumab + GnP (Arm A3) versus GnP alone (Arm A1) by IHC or ctDNA-based biomarkers per all patients (A) or CD73 high only population (B)
Supplementary Figure S1 from A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Authors: Coveler Andrew L. , Reilley Matthew J. , Zalupski Mark , Macarulla Teresa , Fountzilas Christos , Ponz-Sarvisé Mariano , Nagrial Adnan , Uboha Nataliya V. , Frentzas Sophia , Overman Michael , Noonan Anne , Messersmith Wells A. , Pavlakis Nick , Mettu Niharika B. , Bisha Ina , Wang Ying , Smith Paul , Murtomaki Elina , Bielska Agata A. , Bragulat Veronique , Cooper Zachary A. , Kumar Rakesh , Spigel David R.
Published: October 2024

Study design: dose-escalation and dose-expansion phases
Supplementary Table S2 from Integrated Clinical Genotype–Phenotype Characteristics of STAT3-Mutated Myeloid Neoplasms
Authors: Ye Matthew T. , Zuo Zhuang , Calin Steliana , Ye Fengxi , He Hua , Kamata Wataru , Yang Yaling , You M. James
Published: October 2024

Information on STAT3 mutations detected in this study
Figure 1 from A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Authors: Coveler Andrew L. , Reilley Matthew J. , Zalupski Mark , Macarulla Teresa , Fountzilas Christos , Ponz-Sarvisé Mariano , Nagrial Adnan , Uboha Nataliya V. , Frentzas Sophia , Overman Michael , Noonan Anne , Messersmith Wells A. , Pavlakis Nick , Mettu Niharika B. , Bisha Ina , Wang Ying , Smith Paul , Murtomaki Elina , Bielska Agata A. , Bragulat Veronique , Cooper Zachary A. , Kumar Rakesh , Spigel David R.
Published: October 2024

CONSORT diagram for the dose-expansion phase. “a” denotes arm A1: death (n = 1); withdrawal by patient (n = 8); other (n = 4). Arm A3: death (n = 1); withdrawal by patient (n = 2); other (n = 2). “b” denotes patients could be counted more than once in this category if they discontinued different chemotherapy options for different reasons. “c” denotes as permitted per study protocol, patients from arms A2 and A3 continued to receive immunotherapy off-study after the study closure on July 22, 2022, and patients from all arms continued to receive treatment per standard of care at their site. “d” denotes end of study status as defined in the protocol. “e” denotes “sponsor decision" and includes patients either still on treatment or in survival follow-up at the time of study closure. N, number of patients in each treatment group.
Supplementary Table S1 from Integrated Clinical Genotype–Phenotype Characteristics of STAT3-Mutated Myeloid Neoplasms
Authors: Ye Matthew T. , Zuo Zhuang , Calin Steliana , Ye Fengxi , He Hua , Kamata Wataru , Yang Yaling , You M. James
Published: October 2024

Treatment information
Supplementary Data 1 from A Phase Ib Study of Linperlisib in the Treatment of Patients with Relapsed and/or Refractory Peripheral T-cell Lymphoma
Authors: Jin Jie , Cen Hong , Zhou Keshu , Xu Xiaohong , Li Fei , Wu Tao , Yang Haiyan , Wang Zhen , Li Zhiming , Huang Wenyang , Bao Hanying , Xu Zusheng , Qiu Lugui
Published: October 2024

Figure and Tables
Supplementary Table S1 from Second Primary Malignancies after CAR T-Cell Therapy: A Systematic Review and Meta-analysis of 5,517 Lymphoma and Myeloma Patients
Authors: Tix Tobias , Alhomoud Mohammad , Shouval Roni , Cliff Edward R. Scheffer , Perales Miguel-Angel , Cordas dos Santos David M. , Rejeski Kai
Published: October 2024

Joanna-Brigg’s Institute assessment of study bias (Munn et al, 2020, JBI Evid Synth).
Supplementary Material S1 from Second Primary Malignancies after CAR T-Cell Therapy: A Systematic Review and Meta-analysis of 5,517 Lymphoma and Myeloma Patients
Authors: Tix Tobias , Alhomoud Mohammad , Shouval Roni , Cliff Edward R. Scheffer , Perales Miguel-Angel , Cordas dos Santos David M. , Rejeski Kai
Published: October 2024

Systematic Review and Meta-Analysis Protocol according to PRISMA-P guidelines
Table 1 from Remote Neuroinflammation in Newly Diagnosed Glioblastoma Correlates with Unfavorable Clinical Outcome
Authors: Bartos Laura M. , Quach Stefanie , Zenatti Valerio , Kirchleitner Sabrina V. , Blobner Jens , Wind-Mark Karin , Kolabas Zeynep Ilgin , Ulukaya Selin , Holzgreve Adrien , Ruf Viktoria C. , Kunze Lea H. , Kunte Sebastian T. , Hoermann Leonie , Härtel Marlies , Park Ha Eun , Groß Mattes , Franzmeier Nicolai , Zatcepin Artem , Zounek Adrian , Kaiser Lena , Riemenschneider Markus J. , Perneczky Robert , Rauchmann Boris-Stephan , Stöcklein Sophia , Ziegler Sibylle , Herms Jochen , Ertürk Ali , Tonn Joerg C. , Thon Niklas , von Baumgarten Louisa , Prestel Matthias , Tahirovic Sabina , Albert Nathalie L. , Brendel Matthias
Published: October 2024

Characteristics of the cohort.
Supplementary Figure S8 from Second Primary Malignancies after CAR T-Cell Therapy: A Systematic Review and Meta-analysis of 5,517 Lymphoma and Myeloma Patients
Authors: Tix Tobias , Alhomoud Mohammad , Shouval Roni , Cliff Edward R. Scheffer , Perales Miguel-Angel , Cordas dos Santos David M. , Rejeski Kai
Published: October 2024

Subgroup analysis of NRM point estimates stratified by treatment setting.
Supplementary Figure S4 from Second Primary Malignancies after CAR T-Cell Therapy: A Systematic Review and Meta-analysis of 5,517 Lymphoma and Myeloma Patients
Authors: Tix Tobias , Alhomoud Mohammad , Shouval Roni , Cliff Edward R. Scheffer , Perales Miguel-Angel , Cordas dos Santos David M. , Rejeski Kai
Published: October 2024

Subgroup analysis of SPM point estimates stratified by follow-up time.
Supplementary Figure S3 from Second Primary Malignancies after CAR T-Cell Therapy: A Systematic Review and Meta-analysis of 5,517 Lymphoma and Myeloma Patients
Authors: Tix Tobias , Alhomoud Mohammad , Shouval Roni , Cliff Edward R. Scheffer , Perales Miguel-Angel , Cordas dos Santos David M. , Rejeski Kai
Published: October 2024

Subgroup analysis of SPM point estimates stratified by CAR T-cell products.
Figure 1 from Remote Neuroinflammation in Newly Diagnosed Glioblastoma Correlates with Unfavorable Clinical Outcome
Authors: Bartos Laura M. , Quach Stefanie , Zenatti Valerio , Kirchleitner Sabrina V. , Blobner Jens , Wind-Mark Karin , Kolabas Zeynep Ilgin , Ulukaya Selin , Holzgreve Adrien , Ruf Viktoria C. , Kunze Lea H. , Kunte Sebastian T. , Hoermann Leonie , Härtel Marlies , Park Ha Eun , Groß Mattes , Franzmeier Nicolai , Zatcepin Artem , Zounek Adrian , Kaiser Lena , Riemenschneider Markus J. , Perneczky Robert , Rauchmann Boris-Stephan , Stöcklein Sophia , Ziegler Sibylle , Herms Jochen , Ertürk Ali , Tonn Joerg C. , Thon Niklas , von Baumgarten Louisa , Prestel Matthias , Tahirovic Sabina , Albert Nathalie L. , Brendel Matthias
Published: October 2024

Elevated TSPO-PET signals in the non-lesional hemisphere of patients with glioblastoma. A, Patient selection process. Patients receiving TSPO-PET imaging at initial diagnosis of glioma were allocated. Patients with unilateral manifestation of glioblastoma (WHO IV; n = 41) or isocitrate dehydrogenase mutant astrocytoma WHO grade 2 (IDHmut astrocytoma WHO 2; n = 7) at the time of PET were selected for further analysis. B, Patients with newly diagnosed glioblastoma but not patients with IDHmut astrocytoma WHO 2 indicate higher TSPO-PET signal in the contralateral hemisphere compared to healthy controls. Images represent examples of TSPO-PET images of patients with newly diagnosed glioblastoma (left) and IDHmut astrocytoma WHO 2 (middle) in comparison to a healthy control (right). C, Surface projections and axial slices of the group average contralateral TSPO-PET signal of patients with glioblastoma, IDHmut astrocytoma WHO 2, and healthy controls. The non-lesional hemispheres were parcellated into 123 sub-regions using the Brainnetome Atlas. Axial slices show TSPO-PET signals of basal ganglia regions (masked cortical regions). D, Significant TSPO-PET signal elevation in brain regions of the contralateral hemisphere of patients with glioblastoma but not with IDHmut astrocytoma WHO 2 compared to healthy controls. E, Pronounced contralateral TSPO expression in orbito-frontal, superior-temporal, mid-temporal, and mesio-temporal regions of patients with glioblastoma. *, P < 0.01.
Supplementary Data 3 from Metabolomic Prediction of Breast Cancer Treatment–Induced Neurologic and Metabolic Toxicities
Authors: Piffoux Max , Jacquemin Jérémie , Pétéra Mélanie , Durand Stéphanie , Abila Angélique , Centeno Delphine , Joly Charlotte , Lyan Bernard , Martin Anne-Laure , Everhard Sibille , Boyault Sandrine , Pistilli Barbara , Fournier Marion , Rouanet Philippe , Havas Julie , Sauterey Baptiste , Campone Mario , Tarpin Carole , Mouret-Reynier Marie-Ange , Rigal Olivier , Petit Thierry , Lasset Christine , Bertaut Aurélie , Cottu Paul , André Fabrice , Vaz-Luis Ines , Pujos-Guillot Estelle , Drouet Youenn , Trédan Olivier
Published: October 2024

Neurotoxicity
Supplementary Table S1 from Proportional Hazards Violations in Phase III Cancer Clinical Trials: A Potential Source of Trial Misinterpretation
Authors: Lin Timothy A. , McCaw Zachary R. , Koong Alex , Lin Christine , Abi Jaoude Joseph , Patel Roshal , Kouzy Ramez , El Alam Molly B. , Sherry Alexander D. , Noticewala Sonal S. , Fuller Clifton D. , Thomas Charles R. , Sun Ryan , Lee J. Jack , Lin Ruitao , Yuan Ying , Shyr Yu , Meirson Tomer , Ludmir Ethan B.
Published: October 2024

Table S1: Sensitivity analyses of univariable and multivariable logistic regressions using only overall survival (OS) comparisons for trials with co-primary endpoints (PEPs).
Supplementary Table S8 from Evaluating Debio 1347 in Patients with FGFR Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial
Authors: Grivas Petros , Garralda Elena , Meric-Bernstam Funda , Mellinghoff Ingo K. , Goyal Lipika , Harding James J. , Dees E. Claire , Bahleda Rastislav , Azad Nilofer S. , Karippot Asha , Kurzrock Razelle , Tabernero Josep , Kononen Juha , Ng Matthew C.H. , Mehta Rutika , Uboha Nataliya V. , Bigot Frédéric , Boni Valentina , Bowyer Samantha E. , Breder Valeriy , Cervantes Andrés , Chan Nancy , Cleary James M. , Dhawan Mallika , Eefsen Rikke L. , Ewing James , Graham Donna M. , Guren Tormod K. , Won Kim Jin , Koynov Krassimir , Oh Do-Youn , Redman Rebecca , Yen Chia-Jui , Spetzler David , Roubaudi-Fraschini Marie-Claude , Nicolas-Metral Valerie , Ait-Sarkouh Rafik , Zanna Claudio , Ennaji Abdallah , Pokorska-Bocci Anna , Flaherty Keith T.
Published: October 2024

Supplementary Table S8. Progression-free survival according to local assessment (intention-to-treat population).